From Fulcrum Therapeutics press release. Fulcrum plans to launch a Phase 2b clinical trial in FSHD in mid-2019 CAMBRIDGE, Mass., April 23, 2019 – Fulcrum Therapeutics, a biotechnology company focused… Read More »
Fulcrum Acquires Global Rights to a Potential Disease-Modifying Therapy for FSHD
Gear up for World FSHD Day 2019!
Sharpen your orange slicers and polish your selfie sticks! World FSHD Day is on June 20th and you can help us turn social media world orange on that day by… Read More »
The time is now…
In a world awash with billion-dollar profits for drugs to treat the most common ailments ─ hypertension, acid reflux, diabetes, high cholesterol, and so on ─ patients with FSH muscular… Read More »
Newly funded grants
Steps forward toward new treatments The FSH Society’s board of directors voted to approve $332,906 in funding for three grant applications submitted for the August 2018 cycle. The first project… Read More »
FSHD Advocate is out!
The latest issue of our flagship magazine, FSHD Advocate, has left the printers and will be landing soon in your mailbox. To get an advance look, or if you’re a… Read More »